If your doctor told you Viagra "makes you hard," your doctor described the marketing, not the molecule.
PDE5 inhibitors don't generate erections. They block the enzyme that ends them. The erection itself is built by nitric oxide, released only when you're sexually stimulated. No stimulation, no NO, no cGMP, no erection — and the pill does nothing visible.
Think faucet (NO) and drain (PDE5). The pill plugs the drain — it doesn't turn the faucet.
This is why a sildenafil tablet during a boring conference call doesn't embarrass you. The molecule is in your bloodstream. There is simply nothing for it to preserve.
If you stop reading here: PDE5 inhibitors only work with sexual stimulation. No stimulation = no erection. The pill is the brake on cancellation, not the gas. For dose-specific math, see our 50mg vs 100mg breakdown.
Once you understand the cascade, the 4-hour Viagra ceiling makes sense. The blue tinge makes sense. The back pain on Cialis makes sense. The reason sildenafil was discovered by accident makes sense. It's all one chemistry problem.
The cascade: how an erection actually happens
Five steps, in order. Skip one and nothing happens.
1. Sexual stimulation — visual, tactile, mental — fires through parasympathetic nerves into the cavernous nerve.
2. Nitric oxide release. Nerve endings (nNOS) and endothelial cells lining the cavernosal arteries (eNOS) make NO from L-arginine on demand. NO is a tiny gas molecule that diffuses freely across cell membranes.
3. sGC activation, cGMP synthesis. NO binds soluble guanylate cyclase inside the smooth muscle cells. sGC converts GTP to cyclic GMP. Within seconds, cGMP spikes.
4. PKG activation, smooth muscle relaxation. cGMP activates protein kinase G, which phosphorylates downstream targets (myosin light chain phosphatase, calcium-activated potassium channels). Intracellular calcium drops. Smooth muscle relaxes.
5. Blood inflow, venous occlusion. Relaxed cavernosal muscle lets blood pour into the corpora cavernosa. The expansion compresses the subtunical venules against the rigid tunica albuginea. Outflow chokes. Erection.
That's the wiring. A parasympathetic reflex amplified by a calcium-signaling cascade running on a single second messenger: cGMP.
PDE5 inhibitors don't appear in steps 1 through 5. They appear in step 6 — the part that ends the erection.
If you stop reading here: PDE5i = drain plug. No stimulation = no erection. 4-hour ceiling = how fast your liver breaks the drug down.
The drain: PDE5's job is to end the erection
cGMP isn't supposed to stay elevated forever. The body needs an off switch.
That off switch is phosphodiesterase type 5 (PDE5). PDE5 is an enzyme that hydrolyzes cGMP — chops it back into inactive 5'-GMP. As cGMP gets degraded, PKG stops firing, calcium creeps back up, smooth muscle re-contracts, the arterial inflow drops, and the erection subsides.
PDE5 is concentrated heavily in the corpora cavernosa, the lung vasculature, and platelets. The penile concentration is the relevant one here.
Without PDE5, you'd have an unending erection. (This is exactly what happens in priapism — pathological cGMP accumulation that doesn't resolve. It's a urological emergency, not a fun fact.)
Healthy erection physiology is a duel: NO and cGMP build the erection up; PDE5 grinds it back down. In men with vascular ED, the cGMP signal is weaker than the PDE5 grind-down. The erection collapses before it gets fully established, or doesn't sustain.
This is the actual problem PDE5 inhibitors solve.
What the pill actually does (plug the drain, not turn the faucet)
A PDE5 inhibitor binds to PDE5's active site and blocks it from chewing up cGMP.
That's it. The whole mechanism.
If sexual stimulation has happened — and only if — NO is being released and cGMP is being produced. Inhibit PDE5, and that cGMP accumulates instead of getting degraded. The PKG signal stays loud. Smooth muscle stays relaxed. The erection forms more easily and lasts longer.
Here's the metaphor that works: think of the cavernosal smooth muscle as a bathtub. NO is the faucet. PDE5 is the drain at the bottom. PDE5 inhibitors plug the drain.
Plug the drain with no water running, and nothing happens. The tub stays empty. (This is the "no spontaneous erection on a sildenafil tablet" experience.)
Turn the faucet on (sexual stimulation → NO release) with the drain plugged, and the water rises. Fast.
Turn the faucet on with the drain wide open, and you're a man with vascular ED — water comes in, water leaves, the level never gets high enough.
The drug doesn't make water. It just stops the loss.
The 4-hour ceiling is pharmacology, not marketing
Sildenafil's plasma half-life is roughly 4 hours.
Half-life is the time it takes for blood concentration to drop by 50%. After one half-life, you have 50% peak concentration; after two, 25%; after three, 12.5%. By the 6-8 hour mark, sildenafil has fallen below the threshold needed for clinically meaningful PDE5 inhibition in most men.
This is the physical reason "Viagra works for ~4 hours." It's not a marketing decision. It's hepatic CYP3A4 metabolism breaking down the molecule.
You can't engineer your way past it without changing the molecule. Tadalafil, a different PDE5 inhibitor with three carbon rings instead of sildenafil's pyrazolopyrimidinone scaffold, has a 17.5-hour half-life — 4x longer — because of how its structure interacts with CYP3A4 and tissue protein binding. That's why Cialis is a "weekender" and Viagra isn't. It's not better. It's a different timing geometry.
Vardenafil sits near sildenafil at 4-5 hours. Avanafil has a label half-life of about 5 hours but real-world variation up to 17 in some metabolic phenotypes.
The 4-hour Viagra ceiling exists because that's how fast your liver clears the molecule. If your doctor said "take it 30 minutes before, you have a 4-hour window," they were quoting pharmacokinetics, not opinion.
Why each PDE5 inhibitor has a different side effect signature
There are 11 known phosphodiesterase isoforms. PDE5 is the one in penile smooth muscle; the others sit in the retina, heart, lungs, skeletal muscle. A PDE5 inhibitor with perfect selectivity would have no off-target effects. None of them are perfect. Each drug's side effect profile is essentially a map of its cross-reactivity.
Sildenafil → PDE6 → blue tinge. PDE6 controls phototransduction in retinal photoreceptors. Sildenafil hits it ~10x less tightly than PDE5, but at 100mg some inhibition leaks through. About 3% of men report transient blue-green shift. Resolves with the drug.
Vardenafil → better PDE6 selectivity → fewer visual side effects. The imidazotriazinone scaffold gives vardenafil roughly twice sildenafil's PDE5/PDE6 ratio.
Tadalafil → PDE11 → back and muscle pain. PDE11 is in skeletal muscle and testes. Tadalafil hits it at clinically relevant concentrations. Roughly 5-10% of users report dull lower back ache or thigh ache 12-24 hours after dosing. Sildenafil and vardenafil don't have this — they don't hit PDE11 meaningfully.
Avanafil → cleanest profile across PDE6 and PDE11. Designed in the late 2000s specifically for isoform selectivity. Real-world side effect benefit is debated — head-to-head data is sparse.
You can read most of these side effect profiles directly off the selectivity ratios. Pharmacology is doing the work, not folklore.
The accident that started it all
Sildenafil wasn't designed for ED. It was designed for angina.
Pfizer's medicinal chemistry team in Sandwich, Kent, was hunting PDE5 inhibitors in the late 1980s, betting that relaxing coronary smooth muscle would reduce angina episodes. The lead compound — UK-92,480, sildenafil citrate — went into trials in 1991-1992. The angina effect was modest. The drug was on the verge of being shelved.
Then participants in the Welsh cohort started reporting an unexpected side effect: nighttime and morning erections. Some refused to return their unused tablets.
A Pfizer pharmacology team (Boolell, Allen, Ballard, et al.) followed up. By 1996 they had British Journal of Urology data showing sildenafil produced firm erections during sexual stimulation in men with ED. The FDA approved Viagra on March 27, 1998.
The whole modern PDE5 inhibitor class — Viagra, Cialis, Levitra, Stendra, every generic that followed — exists because of a side effect that men in a Welsh angina ward refused to give back.
What to take from this
The pill is not your erection. The pill is a no-cancellation setting on a process your body still has to start.
Practically:
- Sexual stimulation matters. PDE5 inhibitors do not work without it. If you took one and "nothing happened," check that variable before you escalate dose.
- Side effect profile follows isoform selectivity. If sildenafil gave you the blue tinge, vardenafil's better PDE6 selectivity is the rational next try. If tadalafil gave you back pain, that's the PDE11 hit — switch molecules, don't keep dosing through it.
- The 4-hour Viagra window is metabolic, not opinion. If the timing doesn't fit your life, the answer is a longer-half-life molecule (tadalafil), not a higher sildenafil dose.
For dose math (50 vs 100mg), see our 50mg vs 100mg breakdown. For half-life-driven molecule choice across all four, see the 4 PDE5 options article. For brand-by-brand sildenafil ranking inside that lane, see the 6-brand teardown. For the broader ED diagnostic and treatment framework, see the ED pillar.
A note on bias.
We route PDE5-inhibitor orders. Be aware of that.
LiberaCure routes orders to licensed personal-import pharmacies. Suhagra (by Cipla, the WHO-GMP / USFDA-inspected Mumbai giant) is one of the sildenafil products we ship most often. We carry tadalafil, vardenafil, and avanafil generics through the same supply lane, sourced through global pharma giants where available and through ED-export specialists where they aren't. So we have a financial reason to want this article to lead you toward "give it a try."
For reference: Brand Viagra runs $70-100/pill in the US, generic sildenafil $2-5 at CVS, Suhagra $0.40-1/pill at LiberaCure.
Read this with that in mind. The chemistry above is what I'd tell a friend, not what maximizes reorder rate. The pharmacology doesn't care who ships the tablet.
Sources:
- Boolell M et al. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78(2):257-261. (Original Pfizer ED trial — "Welsh accident" follow-up.)
- Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 1999;274(20):13729-13732. (NO-cGMP-PDE5 mechanism reference.)
- Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338:1397-1404. (Pivotal ED trial.)
- Yuan J et al. Comparative effectiveness and safety of oral PDE5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63(5):902-912.
- Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004;16 Suppl 1:S11-S14. (PDE6 / PDE11 cross-reactivity data.)
- Wallis RM et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides. Am J Cardiol 1999;83(5A):3C-12C.
- FDA labels: Viagra (NDA 20-895), Cialis (NDA 21-368), Levitra (NDA 21-400), Stendra (NDA 202-276).
— LiberaCure editorial. We route generic medication through licensed personal-import pharmacies. We don't dispense, prescribe, or warehouse. Read more about why.